Language impairment in Alzheimer's disease and benefits of acetylcholinesterase inhibitors
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease is characterized by progressively worsening deficits in several cognitive domains, including language. Language impairment in Alzheimer's disease primarily occurs because of decline in semantic and pragmatic levels of language processing. Given the centrality of language to cognitive function, a number of language-specific scales have been developed to assess language deficits throughout progression of the disease and to evaluate the effects of pharmacotherapy on language function. Trials of acetylcholinesterase inhibitors, used for the treatment of clinical symptoms of Alzheimer's disease, have generally focused on overall cognitive effects. However, in the current report, we review data indicating specific beneficial effects of acetylcholinesterase inhibitors on language abilities in patients with Alzheimer's disease, with a particular focus on outcomes among patients in the moderate and severe disease stages, during which communication is at risk and preservation is particularly important.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168 · cited 1×
“Patients with AD progress through mild, moderate, and severe stages, and more than half are expected to be at the moderate or severe stages of the disease at any given time (Figure 1).(3,4) Progressive cognitive decline is the fundamental feature of AD symptomatology,(5) and is characterized by episodic memory loss an…”
BackgroundAlzheimer and frontotemporal pathology in subsets of primary progressive aphasia
Mesulam, M., Wicklund, A., Johnson, N., Rogalski, E., Léger, G. C., Rademaker, A., Weintraub, S., & Bigio, E. H. (2008) · Annals of Neurology · doi:10.1002/ana.21388 · Cited by 513
Lam, J. M. C., & Wodchis, W. P. (2010) · Medical Care · doi:10.1097/mlr.0b013e3181ca2647 · Cited by 272 · cited 1×
“To this effect, assessment of healthrelated quality of life in a hospital-based, long-term care patient population showed that language impairments had a stronger association with negative quality of life than did cancer, after controlling for age, gender, and other diagnoses.(18) In addition to predicting quality of…”
BackgroundWhy do people lose their friends after a stroke?: Friendship loss post stroke
Northcott, S., & Hilari, K. (2011) · International Journal of Language & Communication Disorders · doi:10.1111/j.1460-6984.2011.00079.x · Cited by 159
Lethality of Alzheimer Disease and Its Impact on Nursing Home Placement
Arrighi, H. M., Neumann, P. J., Lieberburg, I. M., & Townsend, R. J. (2010) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31819fe7d1 · Cited by 126
The staging and assessment of moderate to severe Alzheimer disease
Feldman, H. H., & Woodward, M. (2005) · Neurology · doi:10.1212/wnl.65.6_suppl_3.s10 · Cited by 105 · cited 3×
“Patients with AD progress through mild, moderate, and severe stages, and more than half are expected to be at the moderate or severe stages of the disease at any given time (Figure 1).(3,4) Progressive cognitive decline is the fundamental feature of AD symptomatology,(5) and is characterized by episodic memory loss an…”
BackgroundVestal, L., Smith-Olinde, L., Hicks, G., Hutton, T., & Hart, J. (2006) · Clinical Interventions in Aging · doi:10.2147/ciia.2006.1.4.467 · Cited by 76 · cited 1×
“Progressive cognitive decline is the fundamental feature of AD symptomatology,(5) and is characterized by episodic memory loss and impairments in attention/concentration, orientation, judgment, visuospatial abilities, executive function, and language.(6) Although the relative importance of the decline in these differe…”
BackgroundVerbal Fluency Predicts Mortality in Alzheimer Disease
Cosentino, S., Scarmeas, N., Albert, S. M., & Stern, Y. (2006) · Cognitive and Behavioral Neurology · doi:10.1097/01.wnn.0000213912.87642.3d · Cited by 54 · cited 1×
“In addition to predicting quality of life, severity of language impairment was suggested to be a predictor of mortality,(19) with verbal frequency being the most significant neuropsychological predictor.(20) An earlier study in elderly patients showed that language impairments were associated with both behavioral and…”
Background
Cited by
Linguistic Features Identify Alzheimer’s Disease in Narrative Speech
Fraser, K. C., Meltzer, J. A., & Rudzicz, F. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150520 · Cited by 797
“Language function especially degrades as the disease progresses through moderate and severe stages [90, 91], and has been shown to improve in response to successful treatment with acetylcholinesterase inhibitors [92].”
Connected Speech in Neurodegenerative Language Disorders: A Review
Boschi, V., Catricalà, E., Consonni, M., Chesi, C., Moro, A., & Cappa, S. F. (2017) · Frontiers in Psychology · doi:10.3389/fpsyg.2017.00269 · Cited by 362
Nanomaterial based drug delivery systems for the treatment of neurodegenerative diseases
Masoudi Asil, S., Ahlawat, J., Guillama Barroso, G., & Narayan, M. (2020) · Biomaterials Science · doi:10.1039/d0bm00809e · Cited by 181
Alzheimer’s disease and language impairments: social intervention and medical treatment
Kuca, K., Maresova, P., Klimova, B., Valis, M., & Hort, J. (2015) · Clinical Interventions in Aging · doi:10.2147/cia.s89714 · Cited by 122
“Furthermore, the loss of communication also has an enormous impact on their quality of life and considerably contributes to their and their caregiver’s burden.(16,18,28) Figure 1 exploration of research studies.”
BackgroundResultInfluentialThe PERK-Dependent Molecular Mechanisms as a Novel Therapeutic Target for Neurodegenerative Diseases
Rozpędek-Kamińska, W., Siwecka, N., Wawrzynkiewicz, A., Wojtczak, R., Pytel, D., Diehl, J. A., & Majsterek, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062108 · Cited by 84
Metadata
- Authors
- Ferris, S., & Farlow, M.
- Venue
- Clinical Interventions in Aging
- Publisher
- Informa UK Limited
- Published
- 2013-08
- Volume
- 8
- Pages
- 1007
- ISSN
- 1176-9092 (ISSN-L)
- 1178-1998
- OpenAlex
- W2087625343
- Cited by
- 181
- References
- 9
- FWCI
- 4.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Language impairment in Alzheimer's disease and benefits of acetylcholinesterase inhibitors. https://app.cochat.ai/papers/10.2147/cia.s39959
- The paper
- Ferris, S., & Farlow, M. (2013). Language impairment in Alzheimer's disease and benefits of acetylcholinesterase inhibitors. Clinical Interventions in Aging. https://doi.org/10.2147/cia.s39959
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.